Thomas Holm Pedersen, NMD Pharma CEO (file photo)

Roche-backed biotech re­fu­els with $40M to steer neu­ro­mus­cu­lar can­di­date to­ward late-stage tri­als

Four years af­ter re­ceiv­ing back­ing from Roche to see if it can carve out a unique path in rare neu­ro­mus­cu­lar dis­or­ders, Aarhus, Den­mark-based NMD Phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.